评价NouvNeu001注射液治疗早发型帕金森病的安全性、耐受性和初步有效性的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability and preliminary efficacy of NouvNeu001 injection in the treatment of early-onset Parkinson's disease
评价立体定向双侧颅内注射NouvNeu001治疗EOPD的安全性、耐受性。
[Translation] To evaluate the safety and tolerability of stereotactic bilateral intracranial injection of NouvNeu001 in the treatment of EOPD.
100 Clinical Results associated with Ruijian Pharmaceutical Technology (Suzhou) Co., Ltd.
0 Patents (Medical) associated with Ruijian Pharmaceutical Technology (Suzhou) Co., Ltd.
100 Deals associated with Ruijian Pharmaceutical Technology (Suzhou) Co., Ltd.
100 Translational Medicine associated with Ruijian Pharmaceutical Technology (Suzhou) Co., Ltd.